According to this latest study, the 2021 growth of Antibiotic API will have significant change from previous year. By the most conservative estimates of global Antibiotic API market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ 5715 million in 2020. Over the next five years the Antibiotic API market will register a -1.3% CAGR in terms of revenue, the global market size will reach US$ 5417.4 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibiotic API market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Penicillins
Cephalosporins
Aminoglycosides
Tetracyclines
Quinolones
Macrolides
Lincomycins
Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Oral Medicine
Injection Medicine

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
UNITED LABORATORIES
North China Pharmaceutical
RUIYING PIONEER PHARMACEUTICAL
Centrient Pharmaceuticals
Aurobindo Pharma
Shyndec Pharmaceutical
Nectar Lifesciences
Harbin Pharmaceutical Group
ACS Dobfar
Novartis
CSPC
QILU ANTIBIOTICS PHARMACEUTICAL
REYOUNG
Orchid Pharma
FUAN PHARMACEUTICAL
Dongying Pharmaceutical
FUKANG PHARMACEUTICAL
Medya Pharmaceutical
LUKANG PHARMACEUTICAL
Dawnrays Pharmaceutical
SALUBRIS
KELUN
HUAFANG PHARMACEUTICAL